<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Elacestrant: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Elacestrant: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Elacestrant: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140698" href="/d/html/140698.html" rel="external">see "Elacestrant: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58024913"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Orserdu</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57840770"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Estrogen Receptor Antagonist;</li>
<li>
                        Antineoplastic Agent, Selective Estrogen Receptor Degrader</li></ul></div>
<div class="block doa drugH1Div" id="F57858049"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Elacestrant 345 mg is equivalent to 400 mg elacestrant hydrochloride, and elacestrant 86 mg is equivalent to 100 mg elacestrant hydrochloride.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="335b3f6d-d18d-4652-b4f1-7933bc7f2839">Breast cancer, advanced or metastatic, ER-positive, HER2-negative, ESR1-mutated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Breast cancer, advanced or metastatic, ER-positive, HER2-negative, ESR1-mutated (postmenopausal patients or males): Oral: </b>345 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35584336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35584336'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If a dose is missed for &gt;6 hours, or if vomiting occurs, skip the dose and administer the next dose the following day at the regularly scheduled time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57858051"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F57858052"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Reduce elacestrant dose to 258 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Avoid elacestrant use.</p></div>
<div class="block dot drugH1Div" id="F57858053"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Elacestrant Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose reduction level </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Elacestrant dosage</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Usual (initial) dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">345 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">First dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">258 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Second dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">172 mg once daily</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Permanently discontinue elacestrant if unable to tolerate 172 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Elacestrant Dosage Modification Recommendations for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Elacestrant dosage modification</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Continue elacestrant at the current dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Consider interrupting elacestrant until recovery to ≤ grade 1 or baseline, then resume elacestrant at the same dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt elacestrant until recovery to ≤ grade 1 or baseline, then resume elacestrant at the next lower dose level.</p>
<p style="text-indent:0em;text-align:left;">If the grade 3 toxicity recurs, interrupt elacestrant until recovery to ≤ grade 1 or baseline, then resume elacestrant with the dose reduced by another dose level.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interrupt elacestrant until recovery to ≤ grade 1 or baseline, then resume elacestrant at the next lower dose level.</p>
<p style="text-indent:0em;text-align:left;">If a grade 4 or intolerable adverse reaction recurs, permanently discontinue elacestrant.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F57858050"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F57853839"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum sodium (16%), hot flash (11%), hypercholesterolemia (30%), hypertriglyceridemia (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%), constipation (12%), decreased appetite (15%), diarrhea (13%), nausea (35%; grade 3: 3%), vomiting (19%; grade 3: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (26%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (17%), increased serum aspartate aminotransferase (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (26%), headache (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (16%)</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (10%), gastroesophageal reflux disease, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea</p></div>
<div class="block coi drugH1Div" id="F57840773"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F57858034"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Dyslipidemia: Hypercholesterolemia and hypertriglyceridemia have occurred in over one-quarter of patients, including grade 3 and 4 events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer based on the presence of ESR1 mutation(s) in plasma using an approved test. Information on approved tests may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=140691" target="_blank">http://www.fda.gov/companiondiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F58024914"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orserdu: 86 mg, 345 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block geq drugH1Div" id="F58031377"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58081563"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Orserdu Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">86 mg (per each): $307.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">345 mg (per each): $922.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F57858029"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Elacestrant is available through specialty pharmacies and specialty distributors. Visit https://www.orserdu.com/ for further information.</p></div>
<div class="block adm drugH1Div" id="F57858054"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with food (to reduce nausea and vomiting) at approximately the same time each day. Swallow tablets whole; do not chew, crush, or split. Do not ingest tablets that are broken, cracked, or appear damaged. If a dose is vomited, skip the dose and administer the next dose the following day at the regularly scheduled time.</p></div>
<div class="block use drugH1Div" id="F57840772"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Breast cancer, advanced or metastatic, ER-positive, HER2-negative, ESR1-mutated:</b> Treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer in postmenopausal patients or adult males with disease progression following at least 1 line of endocrine therapy.</p></div>
<div class="block mst drugH1Div" id="F57858027"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Elacestrant may be confused with fulvestrant.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57878422"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2C9 (minor), CYP3A4 (major), OATP2B1/SLCO2B1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F57878419"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Elacestrant may increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Elacestrant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Elacestrant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Elacestrant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Elacestrant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluoroestradiol F18: Estrogen Receptor Antagonists may diminish the diagnostic effect of Fluoroestradiol F18.  Management: Image patients with fluoroestradiol F-18 prior to starting systemic endocrine therapies that block the estrogen receptor. Use of fluoroestradiol F-18 should not delay indicated treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Elacestrant may increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57858031"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 1 week after the last elacestrant dose. Patients with partners who could become pregnant should also use effective contraception during therapy and for 1 week after the last dose of elacestrant.</p></div>
<div class="block pri drugH1Div" id="F57858032"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, and data from animal reproduction studies, <i>in utero</i> exposure to elacestrant may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F57858033"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if elacestrant is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy and for 1 week after the last elacestrant dose.</p></div>
<div class="block mop drugH1Div" id="F57858056"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Estrogen receptor 1 mutation status. Assess hepatic function; monitor lipid profile prior to therapy initiation and periodically thereafter. Verify pregnancy status prior to treatment (in patients who could become pregnant). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Cardiovascular monitoring for patients with breast cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually in patients with a high 10-year risk (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F57858037"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Elacestrant is an estrogen receptor (ER) antagonist and nonsteroidal selective estrogen receptor degrader (SERD), which degrades estrogen receptor alpha in a dosedependent manner, and inhibits estradiol-dependent estrogen-receptor directed gene transcription and tumor growth (Bidard 2022). In ER-positive, HER2-negative breast cancer cells, elacestrant inhibited 17β-estradiol mediated cell proliferation at concentrations that result in ER-alpha degradation. Elacestrant exhibited antitumor activity in ER-positive, HER2-negative breast cancer models resistant to fulvestrant and cyclin-dependent kinase 4/6 inhibitors, as well as those with estrogen receptor 1 (ESR1) mutations.</p></div>
<div class="block phk drugH1Div" id="F57858038"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Administration of elacestrant (345 mg) with a high-fat meal (800 to 1,000 calories; 50% fat) increased C<sub>max</sub> and AUC by 42% and 22%, respectively (compared to fasted administration).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 5,800 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily via CYP3A4 and, to a lesser extent, via CYP2A6 and CYP2C9.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 30 to 50 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 82% (34% as unchanged drug); urine: 7.5% (&lt;1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 186 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F57858047"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Elacestrant AUC increased by 83% in subjects with moderate hepatic impairment (Child-Pugh class B).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/elacestrant-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35584336">
<a name="35584336"></a>Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. <i>J Clin Oncol.</i> 2022;40(23):3246-3256. doi:10.1200/JCO.22.00338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/elacestrant-drug-information/abstract-text/35584336/pubmed" id="35584336" target="_blank">35584336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/elacestrant-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).<i> Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/elacestrant-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stemline.1">
<a name="Stemline.1"></a>Oserdu (elacestrant) [prescribing information]. New York: Stemline Therapeutics; November 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 140691 Version 21.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
